171 related articles for article (PubMed ID: 9152353)
1. Malaria, mefloquine and the mind.
Ingram RJ; Ellis-Pegler RB
N Z Med J; 1997 Apr; 110(1042):137-8. PubMed ID: 9152353
[No Abstract] [Full Text] [Related]
2. Mefloquine use and hospitalizations among US service members, 2002-2004.
Wells TS; Smith TC; Smith B; Wang LZ; Hansen CJ; Reed RJ; Goldfinger WE; Corbeil TE; Spooner CN; Ryan MA
Am J Trop Med Hyg; 2006 May; 74(5):744-9. PubMed ID: 16687673
[TBL] [Abstract][Full Text] [Related]
3. [Neuropsychiatric symptoms caused by mefloquine (report of several cases)].
Murai Z; Baran B; Tolna J; Szily E; Gazdag G
Orv Hetil; 2005 Jan; 146(3):133-6. PubMed ID: 15693445
[TBL] [Abstract][Full Text] [Related]
4. Mefloquine prophylaxis--revisited.
Cohen J
Aust Fam Physician; 1997 Aug; 26(8):909. PubMed ID: 9267055
[No Abstract] [Full Text] [Related]
5. Neuropsychiatric events and travel: do antimalarials play a role?
Schlagenhauf P; Steffen R
J Travel Med; 2000; 7(5):225-6. PubMed ID: 11231204
[No Abstract] [Full Text] [Related]
6. Health advice for travelers.
Abell L
N Engl J Med; 2000 Oct; 343(14):1045-6. PubMed ID: 11023399
[No Abstract] [Full Text] [Related]
7. Mefloquine for preventing malaria in nonimmune adult travelers.
Cayley WE
Am Fam Physician; 2004 Feb; 69(3):521-2. PubMed ID: 14971832
[No Abstract] [Full Text] [Related]
8. Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine.
Clattenburg RN; Donnelly CL
J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1606-8. PubMed ID: 9394947
[TBL] [Abstract][Full Text] [Related]
9. Methodological concerns regarding the relation between mefloquine and serious psychiatric events in females.
Tepper ML; Strauss BA
J Clin Psychiatry; 2006 Jan; 67(1):164; author reply 164-5. PubMed ID: 16426106
[No Abstract] [Full Text] [Related]
10. [Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug].
Jensen JJ
Ugeskr Laeger; 1998 Apr; 160(16):2413. PubMed ID: 9616091
[No Abstract] [Full Text] [Related]
11. Cognitive and neuropsychiatric side effects of mefloquine.
Javorsky DJ; Tremont G; Keitner GI; Parmentier AH
J Neuropsychiatry Clin Neurosci; 2001; 13(2):302. PubMed ID: 11449039
[No Abstract] [Full Text] [Related]
12. Mefloquine-induced pneumonitis.
Soentjens P; Delanote M; Van Gompel A
J Travel Med; 2006; 13(3):172-4. PubMed ID: 16706949
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of malaria].
Botella de Maglia J; Espacio Casanovas A
Rev Clin Esp; 1999 Aug; 199(8):549-50. PubMed ID: 10522443
[No Abstract] [Full Text] [Related]
14. [Many travellers suffer of side-effects of malaria prophylaxis].
Rietz G; Petersson H; Odenholt I
Lakartidningen; 2002 Jun; 99(26-27):2939-44. PubMed ID: 12170684
[TBL] [Abstract][Full Text] [Related]
15. FDA requires warnings on anti-malaria drug Lariam.
Consum Rep; 2004 Jan; 69(1):45. PubMed ID: 14677548
[No Abstract] [Full Text] [Related]
16. [Psychopathological phenomena in long-term follow-up of acute psychosis after preventive mefloquinine (Lariam) administration].
Meszaros K; Kasper S
Nervenarzt; 1996 May; 67(5):404-6. PubMed ID: 9005352
[TBL] [Abstract][Full Text] [Related]
17. Thrombotic-thrombocytopenic purpura following malaria prophylaxis with mefloquine.
Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Cabassi A; Ariya K; Wirote L
J Antimicrob Chemother; 2006 Jan; 57(1):160-1. PubMed ID: 16286357
[No Abstract] [Full Text] [Related]
18. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.
Overbosch D; Schilthuis H; Bienzle U; Behrens RH; Kain KC; Clarke PD; Toovey S; Knobloch J; Nothdurft HD; Shaw D; Roskell NS; Chulay JD;
Clin Infect Dis; 2001 Oct; 33(7):1015-21. PubMed ID: 11528574
[TBL] [Abstract][Full Text] [Related]
19. [There is no evidence of more symptoms with mefloquine than with other drugs in malaria prophylaxis].
Cobelens FG; van Thiel PP
Ned Tijdschr Geneeskd; 1997 Apr; 141(16):794-5; author reply 796. PubMed ID: 9213805
[No Abstract] [Full Text] [Related]
20. "Serious" and "severe" adverse drug reactions need defining.
Frankenfeld C
BMJ; 2004 Sep; 329(7465):573. PubMed ID: 15345644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
